Literature DB >> 7606498

Amphetamine sensitivity in open-field activity vs. the prepulse inhibition paradigm.

D A Ott1, R J Mandel.   

Abstract

Amphetamine-induced mesolimbic dopamine release has been reported to reduce prepulse inhibition of the acoustic startle response. In addition, it is well known that mesolimbic dopamine stimulation leads to hyperactivity. The present study was undertaken to explore the possibility that one or the other measure may be a more sensitive in vivo indicator of dopamine release in the nucleus accumbens by determining if the amphetamine dose-response curves for these two behavioral measures were different. The data indicate that the dose-response curves obtained for the different behavioral measures are identical. These data are consistent with the idea that the same dopamine terminal field supports both prepulse inhibiton of the acoustic startle response and dopamine-stimulated hyperactivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606498     DOI: 10.1016/0361-9230(94)00276-7

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  3 in total

1.  Ventral striatal noradrenergic mechanisms contribute to sensorimotor gating deficits induced by amphetamine.

Authors:  Karen M Alsene; Katie Fallace; Vaishali P Bakshi
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

2.  Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania.

Authors:  Benício N Frey; Samira S Valvassori; Gislaine Z Réus; Márcio R Martins; Fabrícia C Petronilho; Katrine Bardini; Felipe Dal-Pizzol; Flávio Kapczinski; João Quevedo
Journal:  Neurochem Res       Date:  2006-05-24       Impact factor: 3.996

3.  Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats.

Authors:  Sara A Wahdan; Mariane G Tadros; Amani E Khalifa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-23       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.